PT  - JOURNAL ARTICLE
AU  - Avendaño-Solà, C
AU  - Ramos-Martínez, A
AU  - Muñez-Rubio, E
AU  - Ruiz-Antorán, B
AU  - Malo de Molina, R
AU  - Torres, F
AU  - Fernández-Cruz, A
AU  - Callejas-Díaz, A
AU  - Calderón, J
AU  - Payares, C
AU  - Salcedo, I
AU  - Romera, I
AU  - Lora-Tamayo, J
AU  - Mancheño-Losa, M
AU  - Paciello, ML
AU  - Villegas, C
AU  - Estrada, V
AU  - Saez-Serrano, I
AU  - Porras-Leal, ML
AU  - Jarilla-Fernández, MC
AU  - Paño-Pardo, JR
AU  - Moreno-Chulilla, JA
AU  - Arrieta-Aldea, I
AU  - Bosch, A
AU  - Belhassen-Garcia, M
AU  - López-Villar, O
AU  - Ramos-Garrido, A
AU  - Blanco, L
AU  - Madrigal-Sánchez, ME
AU  - Contreras, E
AU  - Muñiz-Díaz, E
AU  - Domingo-Morera, JM
AU  - Casas-Flecha, I
AU  - Pérez-Olmeda, M
AU  - Garcia-Pérez, Javier
AU  - Alcamí, J
AU  - Bueno, JL
AU  - Duarte, RF
AU  - ,
TI  - Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial
AID  - 10.1101/2020.08.26.20182444
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.26.20182444
4099  - http://medrxiv.org/content/early/2020/09/01/2020.08.26.20182444.short
4100  - http://medrxiv.org/content/early/2020/09/01/2020.08.26.20182444.full
AB  - Background Passive immunotherapy with convalescent plasma (CP) is a potential treatment for COVID-19 for which evidence from controlled clinical trials is lacking.Methods We conducted a multi-center, randomized clinical trial in patients hospitalized for COVID-19. All patients received standard of care treatment, including off-label use of marketed medicines, and were randomized 1:1 to receive one dose (250-300 mL) of CP from donors with IgG anti-SARS-CoV-2. The primary endpoint was the proportion of patients in categories 5, 6 or 7 of the COVID-19 ordinal scale at day 15.Results The trial was stopped after first interim analysis due to the fall in recruitment related to pandemic control. With 81 patients randomized, there were no patients progressing to mechanical ventilation or death among the 38 patients assigned to receive plasma (0%) versus 6 out of 43 patients (14%) progressing in control arm. Mortality rates were 0% vs 9.3% at days 15 and 29 for the active and control groups, respectively (log-rank p=0.056). No significant differences were found in secondary endpoints. At inclusion, patients had a median time of 8 days (IQR, 6-9) of symptoms and 49,4% of them were positive for anti-SARS-CoV-2 IgG antibodies.Conclusions Convalescent plasma could be superior to standard of care in avoiding progression to mechanical ventilation or death in hospitalized patients with COVID-19. The strong dependence of results on a limited number of events in the control group prevents drawing firm conclusions about CP efficacy from this trial. (Funded by Instituto de Salud Carlos III; NCT04345523).Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04345523Funding StatementThis research is funded by the Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III, grant number COV20/00072 (Royal Decree-Law 8/2020, of 17 March, on urgent extraordinary measures to deal with the economic and social impact of COVID-19), co-financed by the European Regional Development Fund (FEDER) A way to make Europe.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Ethics Committee of the Hospital Universitario Puerta de Hierro MajadahondaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be available, including individual patient data after deidentification